|drug325||Aviptadil by intravenous infusion + standard of care Wiki||1.00|
|drug2472||Placebo Comparator Wiki||0.71|
|D055370||Lung Injury NIH||0.18|
|D012127||Respiratory Distress Syndrome, Newborn NIH||0.08|
|D055371||Acute Lung Injury NIH||0.08|
There is one clinical trial.
Novel Corona Virus (SARS-CoV-2) is known to cause Respiratory Failure, which is the hallmark of Acute COVID-19, as defined by the new NIH/FDA classification. Approximately 50% of those who develop Critical COVID-19 die, despite intensive care and mechanical ventilation. Patients with Critical COVID-19 and respiratory failure, currently treated with high flow nasal oxygen, non-invasive ventilation or mechanical ventilation will be treated with Aviptadil, a synthetic form of Human Vasoactive Intestinal Polypeptide (VIP) plus maximal intensive care vs. placebo + maximal intensive care. Patients will be randomized to intravenous Aviptadil will receive escalating doses from 50 -150 pmol/kg/hr over 12 hours.
Description: Cumulative distribution of the time to respiratory failure resolution with concurrent survival through day 28Measure: Resolution of Respiratory Failure Time: Day 0 through day 28
Description: Achievement of score 6-8 on NIAID Ordinal Scale through day 28Measure: Improvement on NIAID Scale (key secondary measure) Time: Day 0 through day 28
Description: Survival probability on Kaplan Meier lifetable through day 28 and day 60Measure: Survival through day 28 and day 60 Time: Day 0 through day 28
Description: Time to discharge from Intensive Care UnitMeasure: Time to ICU discharge Time: Day 0 through day 28
Description: Time on mechanical ventilation, non-invasive ventilation, or high-flow nasal oxygenMeasure: Time on ventilation Time: Day 0 through day 28
Description: Time to extubation (for those initially on mechanical ventilation)Measure: Time to extubation Time: Day 0 through day 28
Description: Time to discharge aliveMeasure: Time to discharge alive Time: Day 0 through day 28 and day 60
Description: Days free of multisystem organ failureMeasure: Multi-organ failure free days Time: Day 0 through day 28
Description: PaO2:FiO2 ratioMeasure: Respiratory Distress while on mechanical ventilation Time: Day 0 through day 28
Description: Oxygenation indexMeasure: Oxygenation index Time: Day 0 through day 28
Description: Improvement in chest x-ray by RALES scoreMeasure: Improvement in chest x-ray Time: Day 0 through day 28
Description: Improvement in IL-6, TNF alpha, and other inflammatory markersMeasure: Improvement in inflammatory markers Time: Day 0 through day 28
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports